Zevra Therapeutics appoints Thomas Anderson to board; Matthew Plooster resigns

ZEVRA THERAPEUTICS, INC.

Thomas Anderson appointed Class III director effective August 7, 2023; term expires at 2024 annual meeting.
Anderson is CEO of SwanBio Therapeutics and former chief commercial strategy officer at Sage Therapeutics.
Anderson receives initial option for 58,800 shares vesting over 3 years and $40,000 annual retainer.
Matthew R. Plooster resigned from the board effective immediately upon Anderson's appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matthew R. Plooster

member of the Board

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-08-07
Filed: August 7, 2023, 7:59 PM ET

On August 7, 2023, Matthew R. Plooster, a member of the Board of the Company, resigned from such position, effectively immediately after the appointment of Mr. Anderson.

Appointed

Thomas Anderson

Class III director

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-08-07
Filed: August 7, 2023, 7:59 PM ET

On August 7, 2023, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Thomas Anderson to serve as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Matthew R. Plooster resigned as member of the Board at ZEVRA THERAPEUTICS, INC..

Action: resigned
Role: member of the Board

Exact text from the filing

On August 7, 2023, Matthew R. Plooster, a member of the Board of the Company, resigned from such position, effectively immediately after the appointment of Mr. Anderson.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas Anderson was appointed as Class III director at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: Class III director

Exact text from the filing

On August 7, 2023, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Thomas Anderson to serve as a director of the Company, effective immediately.

View on SEC.gov

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-022345

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.